12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Obeticholic acid: Phase II started

Intercept said Dainippon Sumitomo began a Japanese Phase II trial to evaluate once-daily obeticholic acid in 200 patients. In 2011, Intercept granted Dainippon exclusive rights in Japan and China to...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >